I'm LongbridgeAI, I can summarize articles.Eli Lilly, UnitedHealth Group, and Intuitive Surgical received Buy ratings from Wall Street analysts on September 14, offering over 20% upside potential. Eli Lilly was upgraded by Berenberg Bank to a Buy with a $1,400 price target, driven by growth in diabetes and obesity treatments like Mounjaro and Zepbound. The stock holds a Strong Buy consensus with an average 12-month target of $1,382.05.
Eli Lilly (LLY), UnitedHealth Group (UNH), and Intuitive Surgical (ISRG) have each received Buy ratings from Wall Street analysts on September 14. Based on their average analyst price targets, the three healthcare stocks offer more than 20% upside potential.
To find more healthcare stocks like these, take a look at TipRanks' Analyst Top Stocks tool. It shows a real-time list of all stocks recently rated by top-ranking analysts.
Eli Lilly (LLY) — Eli Lilly is a global pharmaceutical company whose growth is primarily driven by its diabetes and obesity treatments, including Mounjaro and Zepbound. It also has a broad portfolio of medicines across multiple therapeutic areas. On September 14, Berenberg Bank analyst Luisa Hector upgraded her rating on LLY to Buy, raising the price target to $1,400 from $1,220. According to analyst consensus ratings, LLY has a Strong Buy rating based on 19 Buy, one Hold, and one Sell rating over the past three months. The average12-month price target of $1,382.05 implies an upside of 21.65%.